Wave’s Huntington Drugs Wipe Out As Trials Run Aground
WVE-120102 And WVE-120101 Fail To Show Benefit
Executive Summary
The company now turns to its next-generation Huntington drug, WVE-003.
You may also be interested in...
Roche Tries Again With Failed Huntington’s Drug Tominersen
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.